Y 20487
Latest Information Update: 27 Jun 2002
At a glance
- Originator Mitsubishi Pharma Corporation
- Class Heart failure therapies; Vasodilators
- Mechanism of Action Phosphoric diester hydrolase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Heart failure
Most Recent Events
- 12 Mar 1996 Phase-I clinical trials for Heart failure in Japan (PO)
- 12 Oct 1994 No-Development-Reported for Heart failure in Japan (PO)